



# ***Alpa Laboratories Ltd.***

33/2, Pigdamber A.B. Road - 453 446 Distt. Indore - (M.P.) India

Phone No. : +91-731- 429 4567 Fax No. : +91-731- 429 4444

Email : mail@alpalabs.in

CIN L85195MP1988PLC004446

9<sup>th</sup> February, 2019

To,  
Listing Department,  
BSE Limited.  
Rotunda Building, P J Towers  
Dalal Street, Fort,  
Mumbai – 400 001

To,  
Listing Department,  
National Stock Exchange of India Limited.  
'Exchange Plaza', C-1, Block G,  
Bandra - Kurla Complex,  
Bandra (E), Mumbai – 400 051

Subject: Outcome of Board Meeting under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Reference :- Scrip Code: ALPA ; Scrip Code: 532878 ISIN: INE385I01010

Dear Sir/ Madam,

We refer to our letter dated 31<sup>st</sup> January, 2019 in relation to the intimation of board meeting; this is to inform you that the Board of Directors of the Company at its meeting held today that is on **Saturday, 9<sup>th</sup> February, 2019 at 2.00 p.m. and concluded at 6.00 p.m.** at Registered Office of the Company at Indore. The Board inter-alia has approved the following matter:

1 Approval of the Un-audited Standalone Financial Results of the Company along with Limited Review Report from the Statutory Auditor for quarter ended 31<sup>st</sup> December, 2018.

This is for the information and record of the exchange and members thereof;

You are requested to take the same on records.


Thanking you,

Yours Faithfully

**For Alpa Laboratories Ltd.**

*Mahendra*

Mahendra Singh Chawla  
Director  
DIN-00362058



**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON STANDALONE  
QUARTERLY FINANCIAL RESULTS PURSUANT TO REGULATIONS 33 OF THE  
SEBI LODR REGULATIONS, 2015**

To the Board of Directors of **ALPA LABORATORIES LIMITED**

1. We have reviewed the accompanying statement of unaudited financial results of **ALPA LABORATORIES LIMITED** for the quarter ended **December 31, 2018**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We have conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of  
Anuradha Ratnaparkhi & Associates.  
Chartered Accountants  
Firm Registration No.023451C  
*Anuradha Ratnaparkhi*  
Anuradha Ratnaparkhi  
Proprietor  
Membership Number:075412



Date: February 09, 2019  
Place: Indore



Particulars	Standalone Results					
	Quarter Ended			Nine Month Ended		Year Ended
	Dec-18	Sep-18	Dec-17	Dec-18	Dec-17	Mar-18
	Unaudited					Audited
<b>1. Income</b>						
a) Revenue from operations	2596.05	1590.77	1704.08	5,889.38	4476.43	6226.82
b) Other Income	61.55	95.69	139.99	268.47	403.36	451.44
<b>I. Total income from operations (net) (a+b)</b>	<b>2657.60</b>	<b>1686.46</b>	<b>1844.07</b>	<b>6,157.86</b>	<b>4879.79</b>	<b>6678.26</b>
<b>2. Expenses</b>						
a) Cost of materials consumed	1,483.61	1,173.22	886.50	3,514.88	2,362.47	3,304.56
b) Purchases of stock-in-trade	20.23	17.50	24.71	58.40	161.76	226.66
c) Changes in inventories of fin. goods, stock-in-pro. &	108.11	(263.17)	(46.86)	(18.95)	(28.18)	31.07
d) Employee benefits expense	284.90	274.44	250.81	821.55	740.25	1025.56
e) Finance costs	10.38	20.49	28.47	49.97	89.73	107.15
f) Depreciation and amortization expense	29.34	28.35	32.64	85.26	80.51	112.89
g) Other expenses						
Manufacturing & Operating ( Stores and spares consumed, power & fuel, job work charges contract labour etc.)	112.32	102.85	81.35	314.42	262.68	357.32
Others	312.71	270.43	199.50	793.79	438.64	853.32
<b>Total expenses</b>	<b>2361.56</b>	<b>1624.11</b>	<b>1457.12</b>	<b>5,619.32</b>	<b>4107.86</b>	<b>6018.53</b>
<b>3. Profit/(Loss) before exceptional items and tax (1-2)</b>	<b>296.04</b>	<b>62.35</b>	<b>386.95</b>	<b>538.53</b>	<b>771.93</b>	<b>659.73</b>
<b>4. Exceptional Items</b>	-	-	-	-	-	-
<b>5. Profit/ Loss(-) before tax (3+/-4)</b>	<b>296.04</b>	<b>62.35</b>	<b>386.95</b>	<b>538.53</b>	<b>771.93</b>	<b>659.73</b>
<b>6. Tax (Expenses)/ Benefit</b>						
Current tax	-	-	-	-	-	-188.93
Deferred tax/ Prior Year Taxes	2.01	-	-	16.71	-	10.49
<b>7. Profit/ Loss(-) for the period (5-/+6)</b>	<b>294.02</b>	<b>62.35</b>	<b>386.95</b>	<b>555.25</b>	<b>771.93</b>	<b>481.29</b>
<b>8. Other Comprehensive Income</b>						
(i) (a) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-	-	-
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-	-	-
Total Other comprehensive (loss)/ income (net of tax)	-	-	-	-	-	-
<b>9. Total comprehensive income for the period ( 7+8)</b>	<b>294.02</b>	<b>62.35</b>	<b>386.95</b>	<b>555.25</b>	<b>771.93</b>	<b>481.29</b>
<b>10. Paid-up equity share capital (Face Value ` 10 Each)</b>						
	2104.06	2104.06	2104.06	2,104.06	2104.06	2104.06
<b>11. Other equity ( excluding revaluation reserve)</b>	-	-	-	-	-	8,223.49
<b>12. Debenture Redemption Reserve</b>	-	-	-	-	-	-
<b>13. Basic and Diluted Earnings per share after extraordinary items ` (not annualized)</b>	1.40	0.30	1.84	2.64	3.67	2.29

## Notes -

- The above results have been subjected to Limited Review by the Statutory Auditors, reviewed by Board Audit Committee and have been approved by the Board of Directors at its meeting today.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, read with rule 3 of the Companies ( Indian accounting Standards) Rules, 2015 and Companies ( Indian Accounting Standards ) Accounting Rules, 2016
- The Company is operating in the single segment of Drugs & Chemicals.
- The Provision for Tax may not have been made for the partial/ unaudited periods.
- The Figures of Previous Year/ Periods may have been regrouped/ reclassified wherever necessary.
- The Company adopted indian accounting standards (IND AS ) from 01st April,2017 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (IND AS) 34 Interim Financial Reporting prescribed under section 133 of the companies act,2013
- Proceedings of merger between Alpa Laboratories Limited & its wholly owned subsidiary company i.e Norfolk Mercantile Pvt Ltd. is pending before hon'ble NCLT Mumbai bench, ( M.H.)
- During the Quarter under consideration the Company has made provision of Rs. 20 Lacs towards Liquidated Damages being liability for the quarter under consideration. Till now the Company was recognizing such liability on the basis of actual Claims.

For Alpa Laboratories Ltd.

*Mahendera*  
Mahendra Singh Chawla  
Director  
DIN-00362058